Massachusetts Institute of Technology

NEWDIGS

LEAPS

Learning Ecosystems Accelerator for Patient-centered, Sustainable innovation

Adaptive Reimbursement Panel: Innovating for Patient Access & Better Outcomes for All

2021 ISPOR Annual Meeting

MIT CENTER FOR BIOMEDICAL INNOVATION

Adaptive Reimbursement Panel: Innovating for Patient Access & Better Outcomes for All

Angela Banks
Vice President
External Affairs
UnitedHealth Group

Ronald Potts
Quality Improvement Medical Director,
Kaiser Permanente
National Transplant Services

David Strutton
VP, Global Pharmaceuticals & Policy Research
Center for Observational and
Real-World Evidence
Merck & Co., Inc.

NEWDIGS **Moderator: Mark Trusheim, Strategic Director, MIT NEWDIGS & Visiting Scientist**

Conflict of Interest

- Angela Banks is employed by UnitedHealth Group and holds stock in UnitedHealth Group and AstraZeneca.
- Ron Potts is employed by Kaiser Permanente and Interlink Health Services and has received personal fees from Pfizer.
- Dave Strutton is employed by Merck and is also a stockholder.
- Mark Trusheim is President of Co-Bio Consulting and has received personal fees from Janssen, Merck, Novartis, and Pfizer.

MIT NEWDIGS – Helping the System Catch Up With the Science

- Safe haven **"think & do" tank** for convening; MIT = trusted neutral intermediary
- Track record of **real world impact**
- Interactive methods/tools for **multi-stakeholder collaboration**
- Bold, transformational system innovations **for ten (10) years**

NEWDIGS "Adaptive Licensing" Project fueled timely action & impact in Europe from regulatory science innovation…..


STATE OF THE ART nature publishing group Open

See COMMENTARY page 378

Adaptive Licensing: Taking the Next Step in the Evolution of Drug Approval

H-G Eichler[1,2], K Oye[2,3,4], LG Baird[2], E Abadie[5], J Brown[6], CL Drum[2], J Ferguson[7], S Garner[8,9], P Honig[10], M Hukkelhoven[11], JCW Lim[12], R Lim[13], MM Lumpkin[14], G Neil[15], B O'Rourke[16], E Pezalla[17], D Shoda[18], V Seyfert-Margolis[14], EV Sigal[19], J Sobotka[20], D Tan[12], TF Unger[18] and G Hirsch[2]

… and Illuminated a Broad Set of Principles for Accelerating Sustainable Patient-Centered Innovation

FoCUS

Financing and Reimbursement of Cures in the US

LEAPS

Learning Ecosystems Accelerator for Patient-centered, Sustainable innovation

Learning Lifecycle Connects RWE Planning, Production, & Use

Adaptive Reimbursement Turns Evidence Into Action

It accelerates the USE of RWE findings



from the post-approval RWE PRODUCE platforms

Adaptive Reimbursement Goals: Sustainably Improve Patient Outcomes

- ***Harnessing payment tools to creatively impel clinical use of therapies based on Real-World Evidence (RWE)*** to improve patient outcomes, enhance healthcare system sustainability, and account for value created by upstream innovation.

- ***Creating scalable, Adaptive Reimbursement models*** capable of implementing many RWE findings simultaneously while nimbly adapting to each finding's characteristics and each stakeholder's needs.

- ***Contributing RWD/E to LEAPS*** regarding the therapeutic use changes and outcomes.

- ***Rewarding RWE platforms for generating findings that inform treatment regimens*** by either direct financial support or through indirect mechanisms.

Adaptive Reimbursement May Begin with Outcomes-based Agreements

- **Iterative & Learning** (Lifecycle management, not single contracts)
- Connects to **adjusting value over time** for each stakeholder's metrics



Adaptive Reimbursement Adjusts for Continued Innovation and Knowledge

- Additional indications with differing values and population sizes
- Optimized product population targeting and usage
- Adjunctive therapies



Adaptive Reimbursement More Than Outcomes-based Agreements

- More **uncertainties** such as actuarial risk
- More tools such as stop-loss/reinsurance, subscriptions, warranties, bundles & carve-outs
- More scope to include **polypharmacy and disease regimens including providers & patients**



Adaptive Reimbursement Connects Action to Evidence



Adaptive Reimbursement

Contact Information

- MIT Center for Biomedical Innovation: cbi@mit.edu
- Mark Trusheim: trusheim@mit.edu